Phase I Dose-Escalation Study of BCMA/CS1 Bispecific Chimeric Antigen Receptor (CAR)-T Cells for Relapsed/Refractory Multiple Myeloma
The CART-BCMA/CS1 bispecific CAR-T cell therapy is positioned to address a significant unmet need in the treatment of relapsed/refractory multiple myeloma (MM), particularly for patients who have undergone multiple lines of prior therapy. The market for MM therapies is expanding, with increasing demand for innovative treatments that improve patient outcomes. Given the competitive landscape, which includes established therapies and emerging CAR-T products, successful demonstration of safety and efficacy in this trial could enhance market positioning and attract partnerships or acquisition interest. However, the trial's withdrawal before opening raises concerns regarding feasibility and resource allocation, necessitating further diligence on the sponsor's capabilities and strategic direction.
Indication: Recurrent Multiple Myeloma
Modality: small molecule
Target: B-cell maturation antigen (BCMA) and CS1
Sponsor: Jonsson Comprehensive Cancer Center
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 18, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: B-cell maturation antigen (BCMA) and CS1
View original source fields
Condition raw: Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Condition normalized: Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Modality raw: small molecule
Modality normalized: small molecule
Target raw: B-cell maturation antigen (BCMA) and CS1
Target normalized: B-cell maturation antigen (BCMA) and CS1